XML 84 R54.htm IDEA: XBRL DOCUMENT
v3.24.1.u1

SIGNIFICANT AGREEMENTS AND CONTRACTS - Additional Information (Details) - USD ($) |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 9 Months Ended | 12 Months Ended |
--- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Jul. 26, 2022 | Mar. 31, 2021 | Sep. 03, 2019 | Apr. 22, 2024 | Dec. 31, 2023 | Sep. 30, 2023 | Mar. 31, 2023 | Aug. 31, 2022 | Mar. 31, 2022 | Dec. 31, 2021 | May 31, 2021 | Sep. 30, 2019 | Sep. 30, 2023 | Jun. 30, 2023 | Mar. 31, 2023 | Sep. 30, 2022 | Jun. 30, 2022 | Mar. 31, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | Dec. 31, 2023 | Dec. 31, 2022 | Nov. 30, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  | $ 11,250,000 | $ 7,497,000 | $ 26,107,000 | $ 40,744,000 | $ 6,216,000 | $ 7,269,000 | $ 33,604,000 | $ 13,485,000 | $ 44,854,000 | $ 54,229,000 | $ 59,570,000 | $ 64,448,000 |
Capitalized contract cost, expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 475,000 |  |  | 0 | 40,000 | 0 | 53,000 | 1,772,000 | 77,000 | 0 |
Accounts receivable |  |  |  |  | $ 16,246,000 | $ 3,178,000 | $ 26,121,000 |  | $ 8,783,000 |  |  |  | $ 3,178,000 | $ 5,483,000 | $ 26,121,000 | $ 5,042,000 | $ 4,833,000 | $ 8,783,000 | $ 5,483,000 | $ 4,833,000 | $ 3,178,000 | $ 5,042,000 | 16,246,000 | 5,833,000 |
Mundipharma Medical Company | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative arrangement, cost sharing percentage (as a percent) |  |  | 50.00% |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, maximum cost share |  |  | $ 31,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 31,200,000 |  |
Collaborative agreement, potential transaction value |  |  | $ 568,400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments related to collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000 |  |
Accounts receivable |  |  |  |  | 13,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 13,900,000 | 200,000 |
Mundipharma Medical Company | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  |  |  | $ 11,500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 11,500,000 |  |
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years) |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |
Mundipharma Medical Company | Related Party | Milestone Achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  | $ 11,100,000 |  |  | $ 11,100,000 |  | $ 2,800,000 |  |  |  |  |  |  |  |  |  |  |  |  | $ 25,100,000 |  |
Revenue from collaborative arrangement, excluding revenue from contract with customer, uncredited portion |  |  |  |  | 10,100,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 10,100,000 |  |
Mundipharma Medical Company | Related Party | Milestone Achievement | Subsequent event |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  | $ 2,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Mundipharma Medical Company | Related Party | License Of Intellectual Property |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  | $ 17,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue from collaborative arrangement, excluding revenue from contract with customer, noncurrent liability |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 11,100,000
Mundipharma Medical Company | Related Party | Royalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |
Janssen Pharmaceuticals, Inc. | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, maximum cost share |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 49,800,000 |  |
Payments related to collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 27,000,000 |  |
Collaborative arrangement, termination provisions, required period of written notice (in days) |  | 90 days |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  | 1,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,900,000 | 5,600,000 |
Janssen Pharmaceuticals, Inc. | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  |  |  | $ 3,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,800,000 |  |
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years) |  |  |  |  | 6 months |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 6 months |  |
Janssen Pharmaceuticals, Inc. | Related Party | Upfront Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments related to collaborative agreement |  | $ 27,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen Pharmaceuticals, Inc. | Related Party | R&D Funding |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, potential transaction value |  | 58,200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen Pharmaceuticals, Inc. | Related Party | Development, Regulatory, and Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, potential transaction value |  | $ 695,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen Pharmaceuticals, Inc. | Related Party | Milestone Achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  | $ 7,000,000 |  |  | $ 3,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 10,000,000 |  |
Janssen Pharmaceuticals, Inc. | Related Party | License Of Intellectual Property |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  | $ 26,800,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Janssen Pharmaceuticals, Inc. | Related Party | Royalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 0 | 0 |
Melinta Therapeutics Inc | License Of Intellectual Property |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capitalized contract cost, gross |  |  |  |  | $ 2,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,000,000 |  |
Capitalized contract cost, expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500,000 | 1,800,000 |
Capitalized contract cost, net |  |  |  |  | 200,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 200,000 |  |
Melinta Therapeutics Inc | Milestone Achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Capitalized contract cost, gross |  |  |  |  | 500,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 500,000 |  |
Melinta Therapeutics Inc | Related Party |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, potential transaction value | $ 460,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments related to collaborative agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 30,000,000 |  |
Accounts receivable |  |  |  |  | 400,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 400,000 |  |
Melinta Therapeutics Inc | Related Party | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue, remaining performance obligation, amount |  |  |  |  | $ 3,700,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,700,000 |  |
Revenue, remaining performance obligation, expected timing of satisfaction, period (in years) |  |  |  |  | 2 years |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2 years |  |
Melinta Therapeutics Inc | Related Party | Upfront Payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payments related to collaborative agreement | 30,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Melinta Therapeutics Inc | Related Party | Development, Regulatory, and Commercial Milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative agreement, potential transaction value | $ 430,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Melinta Therapeutics Inc | Related Party | Milestone Achievement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  | $ 20,000,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 20,000,000 |  |
Melinta Therapeutics Inc | Related Party | License Of Intellectual Property |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  | $ 25,900,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Melinta Therapeutics Inc | Related Party | Royalties |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaboration revenue |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 200,000 | $ 0 |

X
- Definition Collaborative Arrangement, Cost Sharing Percentage + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementCostSharingPercentage
Namespace Prefix: | cdtx_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Maximum Third Party Share Of Cost + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementMaximumThirdPartyShareOfCost
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Collaborative Arrangement, Termination Provisions, Required Period Of Written Notice + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementTerminationProvisionsRequiredPeriodOfWrittenNotice
Namespace Prefix: | cdtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Collaborative Arrangement, Transaction, Potential Value + References No definition available. + Details
Name: | cdtx_CollaborativeArrangementTransactionPotentialValue
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Payments Related To Collaborative Agreements + References No definition available. + Details
Name: | cdtx_PaymentsRelatedToCollaborativeAgreements
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Revenue From Collaborative Arrangement, Excluding Revenue From Contract With Customer, Noncurrent Liability + References No definition available. + Details
Name: | cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerNoncurrentLiability
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Revenue from Collaborative Arrangement, Excluding Revenue from Contract with Customer, Uncredited Portion + References No definition available. + Details
Name: | cdtx_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomerUncreditedPortion
Namespace Prefix: | cdtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3 + Details
Name: | us-gaap_CapitalizedContractCostAmortization
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3 + Details
Name: | us-gaap_CapitalizedContractCostGross
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount, after accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479483/340-40-50-3 + Details
Name: | us-gaap_CapitalizedContractCostNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue from collaborative arrangement. Excludes revenue from contract with customer under Topic 606. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 3 -SubTopic 10 -Topic 808 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479428/808-10-45-3 + Details
Name: | us-gaap_RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(1) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_MundipharmaMedicalCompanyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=us-gaap_RelatedPartyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2024-01-01
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=cdtx_LicenseOfIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_JanssenPharmaceuticalsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_UpfrontPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_RDFundingMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_RelatedPartyTransactionAxis=cdtx_DevelopmentRegulatoryAndCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=cdtx_MelintaTherapeuticsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=cdtx_LicenseOfIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_CapitalizedContractCostAxis=cdtx_MilestoneAchievementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |